Article Text

PDF
Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trial
  1. L-S Tam1,
  2. E K Li1,
  3. C-K Wong2,
  4. C W K Lam2,
  5. W-C Li1,
  6. C-C Szeto1
  1. 1Department of Medicine and Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong
  2. 2Department of Chemical Pathology, The Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong
  1. Correspondence to:
    Dr L-S Tam
    tamls_813{at}yahoo.com

Statistics from Altmetric.com

We evaluated the safety and efficacy of leflunomide in patients with lupus nephritis in a prospective open label study. Nineteen consecutive patients who fulfilled the revised American College of Rheumatology criteria for systemic lupus erythematosus (SLE)1 and with proteinuria ⩾2 g/day were invited to participate. The patients were chosen because of previous treatment related toxicities (six patients with severe sepsis) or a contraindication to the use of cyclophosphamide (one patient newly diagnosed with lupus nephritis and cryptococcal meningitis) or lack of response to immunosuppressive treatments including cyclophosphamide (mean (SD) cumulative dose 9 (6) g), azathioprine or ciclosporin for at least 6 months with persistent proteinuria ⩾2 g/day for at least 3 months (12 patients). Two patients were excluded because of increased liver enzymes (one patient) and refusal to give consent (one patient). The study protocol was approved by the local ethics committee and consent forms were signed by all 17 subjects.

Previous immunosuppressive drugs were …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.